Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subunit Influenza Vaccine in Healthy Adults
NCT07854392Phase 4Active, not recruiting
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 4, open-label trial in influenza (2 arms), sponsored by Ab&B Bio-tech Co., Ltd. Primary endpoints: Geometric Mean Titer of Hemagglutination Inhibition Antibodies at 21 days, Geometric Mean Increase of Hemagglutination Inhibition Antibodies at 21 days and 2 more. Started Oct 2026; status: active, not recruiting.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT07854392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854392.